CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Iwilfin (eflornithine) for high-risk neuroblastoma — Coverage Criteria

Defines accepted indications, limits, and documentation requirements for coverage of Iwilfin (eflornithine) in cancer treatment requests submitted to the payer; applies to network providers submitting medication authorization requests.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyIwilfin (eflornithine) for high-risk neuroblastoma — Coverage Criteria

Policy CodePolicy N/A

Change TypeUpdated exclusionsclarified treatment duration

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and support the request with FDA labeling, CMS-recognized compendia, NCCN/ASCO guidelines, or acceptable peer-reviewed literature.

SourceLink

POLICY UPDATE CHANGES

Updated exclusion criteria.

Specified maximum treatment duration of 2 years for indicated use.

Converted to new Evolent guideline template and replaced prior UM ONC_1495 Iwilfin (eflornithine) guideline.

2 yearsmaximum treatment duration for Iwilfin

768 mgsingle dose limit

240monthly tablet maximum

J8999HCPCS code

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Iwilfin (eflornithine)

Maintenance therapy for high-risk neuroblastoma

Covered when ALL of the following are met

Indication and prior therapy: Member is adult or pediatric with high-risk neuroblastoma AND has demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy (e.g., dinutuximab, naxitamab).

Supported by cited literature and compendia

Duration and discontinuation: Treatment may continue until disease progression, unacceptable toxicity, or a maximum of 2 years.2 years

Concomitant therapy restriction: Not to be used concurrently with other anticancer therapies (see exclusion criteria).

Exclusions to coverage include: disease progression while the member is taking Iwilfin (eflornithine); concurrent use with other anticancer therapies; dosing that exceeds the single dose limit of 768 mg; and monthly dosing that exceeds 240 tablets (192 mg) per month.

Iwilfin (eflornithine) is considered investigational and not covered for off‑label indications when the evidence is insufficient or not generally accepted by the medical community. Determinations of sufficiency follow the policy’s evidentiary criteria, including whether the patient and regimen are represented in the published evidence, whether study outcomes are clinically meaningful (for example, ASCO‑recommended thresholds such as hazard ratio < 0.80 or survival benefits of at least 3 months for OS/PFS), and whether the study design and publication type (randomized trials preferred; case reports and abstracts without full peer‑reviewed articles are inadequate) provide acceptable peer‑reviewed support. Uses not supported by CMS‑recognized compendia or acceptable peer‑reviewed literature are excluded.

Regimen	Indication	Duration / Limits	Concurrent therapy	Coverage status
Iwilfin (eflornithine) monotherapy
Maintenance to reduce relapse risk in adult and pediatric members with high-risk neuroblastoma who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy
May be used until disease progression or unacceptable toxicity, or for a maximum of 2 years; dosing limits apply (single dose limit 768 mg; monthly maximum 240 tablets / 192 mg)
Not to be used concurrently with other anticancer therapies
Covered with criteria

Billing and Coding

Covered HCPCS CodesHCPCSCovered

J8999

eflornithine

Single dose limit — Iwilfin (eflornithine)

Single dose limit768 mg

Monthly tablet maximum — Iwilfin (eflornithine)

Monthly tablet maximum240 tablets (192 mg)

Tablet strength equivalentTotal monthly mg = 192 mg (across 240 tablets)

Exclusion if exceededTreatment requests exceeding this monthly limit are excluded

Provider Requirements and Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for all requests for Iwilfin (eflornithine). Providers must submit supporting documentation that demonstrates the requested use is consistent with accepted evidence — FDA-approved product labeling, CMS-recognized compendia, NCCN or ASCO clinical guidelines, or peer-reviewed literature meeting CMS standards. Requests for continuation may be eligible for exemption from a new prior authorization review only when an active authorization was in place within the past year with no lapse greater than 30 days, the member has not experienced disease progression while on Iwilfin, and no additional medications are being added to the continuation request.

Prior authorization required for all new starts and reauthorizations
Continuation exemption: active authorization within last 12 months with ≤30-day lapse, no disease progression, and no added medications
Supporting evidence must include FDA labeling, CMS compendia, NCCN/ASCO guidelines, or acceptable peer-reviewed literature

Prior Authorization

Continuation Exemption

Continuation/renewal requests may be processed without a new prior authorization when the continuation exemption conditions are met: the member has not had disease progression on Iwilfin, the prior authorization was active within the last 12 months without a lapse greater than 30 days, and no additional medications are being added to the regimen. If any of these conditions are not met, a full prior authorization review is required.

Background and Context

Eflornithine (Iwilfin) is used as maintenance monotherapy to reduce the risk of relapse in patients with high‑risk neuroblastoma who have achieved at least a partial response after multiagent, multimodality therapy including anti‑GD2 immunotherapy. Treatment is intended as a post‑immunotherapy maintenance strategy to improve survival outcomes and is administered as single‑agent therapy rather than given concurrently with other anticancer agents.

Definitions

High-risk neuroblastoma (HRNB) — definition and clinical qualifiers

DefinitionHigh-risk neuroblastoma (HRNB): patients with neuroblastoma characterized clinically as high-risk who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy (e.g., dinutuximab, naxitamab).

Permitted useIwilfin (eflornithine) may be used as monotherapy to reduce risk of relapse in adult and pediatric members meeting the HRNB definition.

Duration/limitsTreatment may continue until disease progression, unacceptable toxicity, or a maximum of 2 years.

Concomitant therapy restrictionNot to be used concurrently with other anticancer therapies (see exclusions).

Line of Therapy / Salvage

salvage

Postimmunotherapy maintenance: Used as maintenance (post multiagent multimodality therapy including anti-GD2 immunotherapy) to reduce relapse risk in patients who achieved at least a partial response.